Sonexa Therapeutics

Research & Development

Lead Compound: ST101

ST101 is a small, orally active molecule that is well absorbed and efficiently penetrates the blood-brain-barrier. ST101 is protected by broad composition of matter and method-of-use patents and patent applications, potentially providing market exclusivity through 2030.

ST101 displayed effectiveness in restoring learning and memory capability across a broad array of animal models of cognitive impairment relevant to AD. These include standard models of acute chemical- or lesion-induced amnesia as well as independent animal models that mirror the long-term symptoms and pathology of human AD. The results from these latter two studies demonstrated that ST101 significantly modifies the underlying disease process.